Link copied to clipboard!
Courtecy: AstraZeneca
CoLAB High Throughput Screening system

AstraZeneca’s Global Medicines Development group to expand in Bangalore

IMT News Desk
IMT News Desk
· 2 min read

AstraZeneca India Private Limited (AstraZeneca)’s Global Medicines Development group is building up its hub in Bangalore and recruiting physicians, scientists and regulatory experts as part of plans to support global management of established medicines for its growing portfolio which cover treatments across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases.

AstraZeneca currently employs around 30 experienced physicians and scientists in Bangalore who are engaged in pharmacovigilance activities which support the monitoring of its medicines on the market around the world, and ensure continued safe use for patients. The intent is to expand that team, and to also add regulatory roles and other physician roles to support global management of established medicines. New offices are being set up for the expanding team in Bangalore.

Recruitment is now underway and AstraZeneca is working with experienced recruitment partners to support the search for individuals with the right competence, and in the ambition of completing recruitment by end 2018. The types of roles include:

  • Regulatory Professionals
  • Regulatory Project Managers and Leaders
  • Physicians

This latest expansion forms part of a broader plan in the Global Medicines Development (GMD) group to transform exciting new science and the company’s rich pipeline into more life-changing medicines for patients.

Veena Rajan, Head of Patient Safety, Bangalore within the Global Regulatory, Patient Safety and Quality Assurance group, said: “We are already fortunate to have very talented people working with us in Bangalore, and we are looking to grow that team to build on the excellent work they are delivering in support of our late-stage and mature product portfolio.  As we all know, the Bangalore region, including Mumbai & Chennai, is an expanding area for the pharma industry, including several medical and biopharmaceutical companies, and there are many people here who are furthering their medical education. We aim to benefit from being part of this growing infrastructure and expand on the activities we are already successfully delivering from this location.”

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk